2seventy Bio, Inc.

Apr 30 2:06am ET Leerink Partners Sticks to Their Buy Rating for 2seventy bio (TSVT) by TipRanks Apr 08 7:25am ET Positive Outlook for 2seventy bio’s ABECMA: Buy Rating Affirmed Amidst Expansion and Competitive Dynamics by TipRanks Apr 07 4:22pm ET 2seventy Bio price target raised to $12 from $9 at Citi by TipRanks Apr 07 3:05pm ET Buy Rating and High Risk for 2seventy bio: FDA Approval and Market Expansion Fuel Optimistic Outlook by TipRanks Apr 05 9:32am ET 2seventy bio’s Abecma Wins FDA Approval for Multiple Myeloma by TipRanks Apr 05 9:08am ET Bristol Myers, 2seventy Bio’s Abecma approved by U.S. FDA by TipRanks Apr 01 2:55pm ET Fly Insider: 2seventy bio, Coinbase among week’s notable insider trades by TipRanks Apr 01 8:02am ET 2seventy bio Finalizes Asset Sale and Executive Transition by TipRanks Mar 20 5:32pm ET 2seventy bio Reinforces Board, Faces Engine Capital Nominations by TipRanks Mar 18 7:15am ET TD Cowen Sticks to Its Hold Rating for 2seventy bio (TSVT) by TipRanks Mar 18 7:12am ET 2seventy bio CSO Exits, Abecma Advances with FDA Committee by TipRanks Mar 15 7:00pm ET 2seventy bio trading resumes by TipRanks Mar 15 6:30pm ET Bristol Myers, 2seventy Bio: FDA’s ODAC votes in favor of Abecma by TipRanks Mar 15 1:00pm ET 2seventy bio trading halted, news pending by TipRanks Mar 14 7:36am ET TD Cowen Sticks to Their Hold Rating for 2seventy bio (TSVT) by TipRanks Mar 14 7:17am ET Optimistic Outlook for 2seventy bio’s ABECMA Ahead of FDA Panel Review: A Buy Rating Justified by TipRanks Mar 06 11:20pm ET Buy Rating Affirmed for 2seventy bio on FDA Meeting and Strong Financial Outlook by TipRanks Mar 06 6:31am ET Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), 2seventy bio (TSVT) by TipRanks Mar 06 6:22am ET 2seventy Bio price target lowered to $12 from $20 at Canaccord by TipRanks Mar 05 7:32am ET 2seventy Bio: Abecma generated $56M U.S. commercial revenue in Q4 by TipRanks Mar 05 7:28am ET 2seventy bio: Close of asset sale to Regeneron seen in 1H24 by TipRanks Mar 05 7:19am ET 2seventy Bio reports Q4 EPS ($1.11), consensus (99c) by TipRanks Feb 06 4:11am ET 2seventy bio and BMS Schedule FDA Panel for Abecma by TipRanks Feb 05 7:02am ET Bristol Myers and 2seventy Bio’s application for Abecma to be reviewed by FDA by TipRanks Feb 03 12:47pm ET Buy Rating Affirmed for 2seventy bio Amidst Revenue Stabilization and Strategic Growth Initiatives by TipRanks Jan 31 7:33am ET 2seventy Bio upgraded to Outperform at Leerink on acquisition potential by TipRanks Jan 31 7:20am ET 2seventy Bio upgraded to Outperform from Market Perform at Leerink by TipRanks Jan 30 4:24pm ET 2seventy Bio cut to Market Perform at TD Cowen as outlook hinges on Abecma by TipRanks Jan 30 4:18pm ET 2seventy Bio downgraded to Market Perform from Outperform at TD Cowen by TipRanks Jan 30 7:23am ET 2seventy Bio names Chip Baird CEO, Vicki Eatwell CFO upon transaction closing by TipRanks Jan 30 7:17am ET 2seventy Bio to focus on Abecma commercialization with Bristol Myers Squibb by TipRanks